Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib vs placebo in PDGFRA D842V-mutant advanced or metastatic GIST
2015-000287-34Phase 3Active
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastrointestinal stromal tumor (GIST) comparing Crenolanib arm with Placebo arm (2 arms). Primary endpoint: Progression-free survival. Started Oct 2016; status: active.
02
Drugs
crenolanib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2015-000287-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000287-34.